Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Batroxobin”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 433 records · Page 24Linked to original sources
PubMed1977

The reversible antithrombin activity of incubated plasma.

The thrombin time of normal citrated plasma is progressively prolonged on incubation in open glass tubes at 37 degrees C. The phenomenon is dependent on the temperature and duration of incubation, on the pH, and on the concentration of calcium ions present. Platelet-rich citrated plasma fails to exhibit augmented antithrombin activity when similarly incubated, and the addition of washed platelets to platelet-poor plasma inhibits this activity. The clot retarding action of incubated plasma against thrombin is also manifested against Arvin (Ancrod), but not against Reptilase-R. This thrombin time lengthening may be inhibited by incubation with anti-antithrombin III antiserum thus indicating that the phenomenon of thrombin time lengthening is consistent with enhanced activity of antithrombin III. It is unlikely that alterations in the activity of alpha2-macroglobulin, is important in the reduced thrombin-coagulability of incubated plasma. Interference with the polymerisation of fibrin monomers by the physico-chemical changes may contribute to the observed phenomenon.

Ancrod↗
PubMed1978

[Coagulometer H21: an automatic apparatus for coagulation study (author's transl)].

We describe and present a new automatic device to measure the clotting time of a plasma plus reagent mixture by recording the time of transformation : solution to gel. The apparatus is able to perform 50 tests without manual help. Indeed it automatically carries out:--the dispatching of the tested plasma,--the dispatching of the various reagents,--the recording of the clotting time of the sample,--the processing of the data through greater a printer. No contamination is allowed to occur since the tubing and the plates containing the sample are disposable. We obtain accuracy than with the manual method with a coefficient of variation below 3%.

Autoanalysis↗
PubMed1978

Influence of heparin and defibrase on transplantability of syngeneic tumors in mice.

It had been previously demonstrated that fibrin clot might have an important role in the growth of malignant tumors and in metastasis formation. For this reason an attempt had been made to find out whether inhibition of fibrin formation by heparin or fibrinolysis induced by defibrase could limit tumor growth. Male mice of inbred strain were challenged with suspension of tumor cells. For anticoagulation and/or fibrinolytic therapy two different schedules were used. The treatment was started either simultaneously with the tumor transplantation, or one week prior to the injection of tumor cells. The size of tumors was bigger in the group of treated animals, when compared with the controls. However, the difference was not statistically significant. On the other hand, frequency of implanted tumors was significantly higher in animals with heparin and defibrase treatment or pretreatment.

Animals↗
PubMed1995

Ethnic variations in the haemostatic system: comparison between Arabs, Westerners (Europeans and Americans), Asians and Africans.

A wide variety of haemostatic variables were measured in healthy male subjects predominantly blood donors residing in Riyadh, the capital city of Saudi Arabia. Subjects were divided according to ethnic origin: Saudi Arabs n = 487, Westerners (Europeans and Americans) n = 300, South East Asians (Koreans and Filipinos) n = 360, and West Africans n = 82. There were no significant differences in prothrombin time, partial thromboplastin time, thrombin time, reptilase time, plasma fibrinogen, antithrombin, plasminogen and platelet count between Saudis, Westerners and Asians. Africans exhibited significantly lower plasma levels of fibrinogen, platelet count and plasminogen than other ethnic groups. Arabs and Africans had higher levels of FVIII:C and vWF:ristocetin cofactor than Westerners. On the other hand, FX was significantly higher in Westerners than in other ethnic groups. Smokers had higher fibrinogen levels than non-smokers. These variations, which could not be related to blood group distribution, physical parameters of height and weight, may be due to genetic and/or dietary habits. In conclusion, this study established the existence of racially determined variations in haemostatic variables, with Black Africans showing changes consistent with a lesser tendency towards atherosclerosis and cardiovascular disease than other ethnic groups. These variations should be taken into account when investigating the haemostatic system in patients.

Adolescent↗
PubMed1995

[Compositive treatment of acute deep vein thrombosis of lower extremity].

Fourteen patients with acute deep vein thrombosis of lower extremity (DVT) were treated with composite methods including thrombectomy (iliofemoral venous thrombectomy and ascending venous thrombectomy), thrombolytic and anticoagulant therapy. Follow-up for 2-27 months (average 11.5 months) showed excellent and good results in 78.6%, and the morbidity of post-thrombotic syndrome only 21.4%. The remarkable results were due to opening of occlusive vein of the lower extremities by thrombectomy, which could make thrombolytics effective and reduce the dose of thrombolytics to prevent bleeding complication. Ascending venous thrombectomy could not only remove the venous thrombi of the lower extremities but also protect the deep venous valves and reduce the morbidity of postthrombotic syndrome. Additionally, to reach a satisfied therapy, lesion in iliac vein, such as anatomical compression, stenosis, occlusion, diaphragm and so on, shall be managed as well. Otherwise, DVT shall be recurrent.

Adult↗
PubMed1994

Intraocular hemocoagulase in human vitrectomy.

A prospective study was performed to establish the effects on the bleeding time and the ocular toxicity of the use of intravitreal hemocoagulase (1 NIH thrombin unit/100 ml in BSS Plus) in patients undergoing vitrectomy. Sixty patients with diabetic retinopathy, penetrating ocular injury or non-diabetic retinal vascular disorder, in whom electroretinograms were recordable, were assigned to a study of Hemocoagulase-BSS Plus versus BSS Plus. The bleeding time was measured after cutting the proliferative attachments to the underlying retina. Intravitreal hemocoagulase significantly reduced the bleeding time, and this reduction of bleeding facilitated the surgery. A washout of hemocoagulase at the completion of the vitrectomy was not carried out. Hemocoagulase in the vitreous cavity assisted in maintaining hemostasis during the first week after diabetic vitrectomy. Postoperative electroretinography data did not show any disadvantage for the hemocoagulase infusate. Clinical study showed no adverse effect on the cornea, lens or visual acuity.

Adolescent↗
PubMed1993

Efficacy of intravitreal hemocoagulase for control of bleeding in rabbit experimental model of vitrectomy.

Hemorrhage during vitrectomy for diabetic retinopathy or in the recently traumatized eye can complicate the surgical procedures and might cause termination and failure of vitrectomy in some cases. The effect of the hemocoagulase, Botropase, on the hemostasis of intraocular bleeding was evaluated in a rabbit model by cutting central retinal vessels in the medullary ray. Addition of the hemocoagulase (1 NIH unit/100 ml) to BSS Plus significantly reduced bleeding time. Immediately after vitrectomy with the use of this hemocoagulase, the average of the maximum amplitudes of the b-wave in electroretinography was normal, although the sensitivity of the electroretinogram was reduced by 0.1 log unit in the experimental eyes which were infused with hemocoagulase solution. The sensitivity showed no significant difference after the second postoperative day. The experimental eyes showed no abnormal findings histologically. Infusate containing Botropase appeared to be a useful adjunct for the control of intraocular bleeding during vitreous surgery.

Animals↗
PubMed1995

[Clinical application of endoscopic injection of medication for stopping gastric bleeding].

The authors studied 40 patients with bleeding from peptic ulcer or gastric carcinoma, and evaluated the therapeutic effects of endoscopic injection of absolute alcohol and Bathroxobin. Among them, 20 patients were given absolute alcohol and the remaining 20 Bathroxobin (Reptilase). Absolute alcohol was injected submucosally at 4-6 pinpoints around the bleeding site (0.1-0.2ml/dose, total dose 0.5-1.2ml); Bathroxobin was injected similarly (1 kU/dose, total dose 0.5-1.0kU). Treatment failed in one patient receiving alcohol because of spouting artery bleeding and surgery was resorted to finally. The other 39 patients had successful stopping of the bleeding in one time. The effective rate is 97.5 percent (39/40) and the rate of re-bleeding is low. It is thus shown that endoscopic submucosal injection of absolute alcohol and Bathroxobin for stopping gastric bleeding is safe, simple and effective. However, more experience is needed in this respect.

Adult↗
PubMed1977

[Fibrinogen Zürich I: defective fibrinopeptide-A release].

Fibrinogen Zurich I (FZI) is characterized by delayed fibrin monomer aggregation. It has been previously shown that the patient fibrinogen is composed of two populations of molecules, one aggregating normally and the other not aggregating at all but interfering with the aggregation of the normal population. By use of a radioimmunoassay for fibrinopeptide A (FPA), only approximately half of the expected FPA could be recovered after thrombin and Defibrase proteolysis. Even after exhaustive proteolysis with 2 thrombin units of Defibrase, no further release of FPA could be obtained. The defective FPA release was confirmed by measurement of the N-terminal Gly/Tyr ratio. It may be assumed that the abnormal aggregation of one fraction of FZI is due to the defective FPA release from this fraction.

Batroxobin↗